CopyMark Law Group
4.9/5
Drawing for AIM IMMUNOTECH

USPTO serial 88588324

AIM IMMUNOTECH

Reviewed by CopyMark Law Group

Reg. 7458330Status 700Registered
Filing date
Status date
Registration date
Jul 23, 2024
Examiner
EULIN, INGRID C
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with AIM IMMUNOTECH?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Trademark Monitoring
(312) 319-4460
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Start a new application
(312) 319-4460

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

DONNA J. BUNTON

DONNA J. BUNTON NIXON & VANDERHYE P.C.901 NORTH GLEBE ROAD, 11TH FLOORARLINGTON, VA 22203United States

Goods and services

ClassDescriptionStatusFirst use
005Intravenous solution for use in the treatment of viral infections, immune disorders, cancer and ME/CFS; intravenous solution for use in the treatment of viral infections, immune disorders, cancer and ME/CFS; intravenous solution for use in the treatment of injuries resulting from surgery, thermal accidents or burns; Interferons; Parenterally administered interferon for use in treating viral diseases, immunological disorders and cancer; Pharmaceutical products, namely, pharmaceutical preparations for treatment of viral and infectious diseases, cancer, immune disorders and ME/CFS; intranasal solutions for use as a vaccine adjuvant, all of the foregoing primarily available by prescriptionACTIVEJun 7, 2023
042Pharmaceutical research and development; Pharmaceutical research and development of drugs for the treatment of cancers, viral diseases, immunological disorders and ME/CFSACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jul 23, 2024NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Jul 23, 2024R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jun 20, 2024SUNANOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED—
Jun 20, 2024CNPRALLOWED PRINCIPAL REGISTER - SOU ACCEPTED—
Jun 18, 2024TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jun 18, 2024CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jun 18, 2024ALIEASSIGNED TO LIE—
Feb 9, 2024TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Feb 9, 2024TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Nov 9, 2023XELGAPPLICATION EXTENSION GRANTED/RECEIPT PROVIDED—
Nov 9, 2023XELRAPPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED—
Aug 9, 2023GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 9, 2023GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 9, 2023CNRTSU - NON-FINAL ACTION - WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 19, 2023SUPCSTATEMENT OF USE PROCESSING COMPLETE—
Jul 19, 2023AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Jun 23, 2023IUAFUSE AMENDMENT FILED—
Jun 23, 2023EISUTEAS STATEMENT OF USE RECEIVEDThe applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action.
Mar 2, 2023EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Feb 28, 2023EX3GSOU EXTENSION 3 GRANTED—
Feb 28, 2023EXT3SOU EXTENSION 3 FILED—
Feb 28, 2023EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Sep 2, 2022EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Aug 31, 2022EX2GSOU EXTENSION 2 GRANTED—
Aug 31, 2022EXT2SOU EXTENSION 2 FILED—
Aug 31, 2022EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Mar 2, 2022EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Feb 28, 2022EX1GSOU EXTENSION 1 GRANTED—
Feb 28, 2022EXT1SOU EXTENSION 1 FILED—
Feb 28, 2022EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Aug 31, 2021NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Jul 20, 2021TMBNTTAB RELEASE CASE TO TRADEMARKS—
Jul 20, 2021OP.TOPPOSITION TERMINATED NO. 999999—
Jul 20, 2021OP.DOPPOSITION DISMISSED NO. 999999—
Jul 23, 2020DOCKASSIGNED TO EXAMINER—
Jun 29, 2020OP.IOPPOSITION INSTITUTED NO. 999999—
Jan 9, 2020ETOFEXTENSION OF TIME TO OPPOSE RECEIVED—
Dec 31, 2019NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Dec 31, 2019PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Dec 11, 2019NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Nov 25, 2019CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Nov 22, 2019DOCKASSIGNED TO EXAMINER—
Oct 9, 2019ASGNAUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP—
Sep 6, 2019NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Aug 26, 2019NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance